The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Gilead Sciences has | Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was ...

CVS released a statement to News 8 and provided more details on its investments, colleague support initiatives, and the acquisition of Rite Aid prescription files.